SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A sharp selloff across AI neocloud stocks, fueled by concerns about financing costs and whether the sectors business models can deliver returns, has put NBIS in focus. Traders are split between viewing the drop as an overdone, oversold pullbackwith some citing NBISs stronger financial positionand expecting more downside amid lingering sector risks.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgrade to Buy has fueled a rebound discussion after a sharp selloff, with some traders seeing the decline as overdone and others warning that CoreWeaves heavy debt and financing needs remain a risk. The debate centers on whether AI demand and contracted business can outweigh concerns about borrowing costs and the companys ability to fund its expansion.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is drawing attention after stronger-than-expected third-quarter results and a sharply higher 2027 adjusted EBITDA outlook. Bulls are highlighting the improved outlook and potential short-covering, while skeptics question whether operating gains can ease the companys substantial debt burden.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The prolonged wait for the 80th death event in SELLASs blinded Phase 3 REGAL trialand the final analysis of its GPS treatment for AMLis driving attention amid share-price weakness. Bulls interpret the delay and upcoming ASH meeting as possible signs of extended survival or data disclosure, while skeptics say the timeline and CEOs comments prove nothing; no outcome has been confirmed, and traders also watch for SLS009 data.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

OCUL is drawing attention around AXPAXLIs prospects in wet AMD after competitor EyePoints trial setback. Some traders see fewer competitive threats and emphasize AXPAXLIs potential durability, while others argue the setback could fuel broader skepticism about TKI treatments; debate also centers on the companys pending NDA submission.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

Traders are focused on XEs sharp post-IPO selloff, often blaming lockup-related share supply and weakness across nuclear and AI-linked stocks; concerns about the long path to commercialization and permitting also weigh on sentiment. Some holders remain bullish on Amazons backing and future data-center power demand, while others warn the selling may continue.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

The FDAs clearance to expand Alpha Taus U.S. REGAIN recurrent-glioblastoma trial from 10 to 20 patients is drawing attention, alongside expectations for additional clinical data at the SNO meeting. Traders are broadly optimistic about the growing catalyst pipeline, while the early GBM results come from a very small cohort; completion of enrollment in the pancreatic IMPACT study is also contributing to the discussion.

Dynex Capital, Inc. is an internally managed mortgage real estate investment trust. It engages in the business of investing in mortgage-backed securities. The company was founded on December 18, 1987 and is headquartered in Glen Allen, VA.

Dynex Capital, Inc.

Dynexs Q3 results are drawing attention after wider mortgage spreads drove a sharp decline in book value and a reported loss, while earnings fell short of covering the monthly dividend. Traders are debating dividend sustainability and added risk from higher leverage, though some view the losses as largely unrealized and continue to favor the income stream.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

A broad biotech selloff, attributed by traders to rising-rate concerns, risk-off positioning and rotation away from smaller biotech stocks, is weighing on XBI. The community is split between expecting further weakness and viewing the sharp pullback as an oversold buying opportunity, with potential M&A and upcoming clinical catalysts cited as reasons for optimism.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

A sharp, high-volume rebound after a steep AI-infrastructure selloff has drawn attention to WULF, with traders highlighting CEO Paul Pragers CNBC defense of its power-and-data-center leasing model, which avoids owning rapidly depreciating chips, and bullish Morgan Stanley commentary. The community is split between viewing the move as a possible reversal and worrying that financing costs, leverage, and broader sector weakness could bring renewed selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are BWIN, PTC, FULC, PRTH Obtaining Fair Deals for their Shareholders?

Are BWIN, PTC, FULC, PRTH Obtaining Fair Deals for their Shareholders? Are BWIN, PTC, FULC, PRTH Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 12, 2026Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

Are FULC, TCBK, LXP Obtaining Fair Deals for their Shareholders?

Are FULC, TCBK, LXP Obtaining Fair Deals for their Shareholders? Are FULC, TCBK, LXP Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 25, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

Are FULC, WEAV, BWIN Obtaining Fair Deals for their Shareholders?

Are FULC, WEAV, BWIN Obtaining Fair Deals for their Shareholders? Are FULC, WEAV, BWIN Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 18, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

Are ARX, FULC, EFSI Obtaining Fair Deals for their Shareholders?

Are ARX, FULC, EFSI Obtaining Fair Deals for their Shareholders? Are ARX, FULC, EFSI Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 15, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

Are FULC, WEAV, TECH Obtaining Fair Deals for their Shareholders?

Are FULC, WEAV, TECH Obtaining Fair Deals for their Shareholders? Are FULC, WEAV, TECH Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Sept. 9, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) and Slate Medicines, Inc. Upon closing of the proposed transaction, Fulcrum shareholders are expected to own 5.0% of the combined company.Halper Sadeh encourages Fulcrum...

Are UTZ, ITGR, FULC Obtaining Fair Deals for their Shareholders?

Are UTZ, ITGR, FULC Obtaining Fair Deals for their Shareholders? Are UTZ, ITGR, FULC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Sept. 2, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

Are UTZ, VCTR, FULC, CZR Obtaining Fair Deals for their Shareholders?

Are UTZ, VCTR, FULC, CZR Obtaining Fair Deals for their Shareholders? Are UTZ, VCTR, FULC, CZR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 28, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

Are WEAV, FULC, BRBS Obtaining Fair Deals for their Shareholders?

Are WEAV, FULC, BRBS Obtaining Fair Deals for their Shareholders? Are WEAV, FULC, BRBS Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 24, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC

$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC $HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC PR Newswire NEW YORK, Aug. 23, 2026 NEW YORK, Aug. 23, 2026 /PRNewswire...

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

Fulcrum Therapeutics Inc

Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? 

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Fulcrum shares plunged to a 52-week low of about $2.90 after the company halted development of its lead sickle cell disease drug, pociredir.</li><li>Heron shares fell to a record low of $0.44 after a federal court invalidated patents covering its cancer-supportive care drug CINVANTI.</li><li>MicroVision shares slumped after the company proposed a reverse stock split.&nbsp;</li></ul>Fulcrum Therapeutics (FULC), Heron Therapeutics (HRTX) and MicroVision (MVIS) suffered steep losses on Tuesday, with each stock falling to fresh 52-week lows as investors reacted to significant setbacks affecting their core business prospects.<a href="https://stocktwits.com/symbol/FULC">Fulcrum Therapeutics</a> and&nbsp;<a href="https://stocktwits.com/symbol/HRTX">Heron Therapeutics</a> stocks plunged by over 51% and 45%, respectively, and&nbsp;<a href="https://stocktwits.com/symbol/MVIS">MicroVision stock&nbsp;</a>slumped by nearly 32%.&nbsp;<h2 class="st-heading-2">FULC Faces Pipeline Crisis</h2>Fulcrum recorded the largest decline of the group, with shares tumbling to a 52-week low of $2.9, as the company announced on Monday that it would discontinue development of pociredir, its leading treatment candidate for sickle cell disease.The move came after the U.S. Food and Drug Administration raised concerns about possible cancer risks linked to the treatment. Since the drug was a major part of Fulcrum’s growth plans, analysts lowered their expectations for the company.&nbsp;Following the development, Fulcrum faced a wave of analyst downgrades on Tuesday. JPMorgan downgraded the stock by two levels, moving it to ‘Underweight’ from ‘Overweight’.According to JPMorgan, Fulcrum's ongoing strategic review may not be enough to offset the impact of losing its lead asset. Leerink also adopted a more cautious stance, downgrading FULC stock to ‘Market Perform’ from ‘Outperform’. The firm simultaneously slashed its price target to $4 from $24.However, on Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory.&nbsp;<h2 class="st-heading-2">Patent Setback Hits HRTX</h2>Heron also came under heavy pressure with the stock plunging to a record low of $0.44 after a federal court ruling invalidated patents tied to CINVANTI, one of the company’s important cancer-supportive care products.The ruling could allow generic versions of the drug to enter the market sooner than expected, hurting Heron’s sales. CEO Craig Collard said the company will appeal the decision.&nbsp;Following the update, Needham downgraded Heron to ‘Hold’ from ‘Buy’. Retail sentiment around the stock changed to ‘extremely bullish’ from ‘bullish’ territory the previous day.&nbsp;<h2 class="st-heading-2">MVIS Seeks Reverse Stock Split Approval&nbsp;</h2>MicroVision stock hit a 52-week low of $0.4 after the company asked its shareholders to approve a reverse stock split proposal. The proposal will be presented at the company's virtual annual shareholder meeting scheduled for July 10, where investors will vote on several measures.If successful, MicroVision's board would gain the ability to combine shares at a ratio ranging from 1-for-5 to 1-for-15. The lidar company said the measure is intended to support compliance with Nasdaq's minimum bid-price requirement. Retail sentiment around the stock remained in ‘bearish’ territory.&nbsp;So far this year, MVIS, FULC, and HRTX stocks have plunged between 50% and 72%.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/black-berry-stock-surges-overnight-cfo-ai-vision-retail-debates-meme-mania-growth-story/cZ0SpWqReDn">BlackBerry Stock Surges Overnight As CFO Stands Firm On AI Vision — Retail Debates Meme Mania Vs Growth Story</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Fulcrum Therapeutics logo is seen displayed on a smartphone screen.

Fulcrum Therapeutics (FULC), Heron Therapeutics (HRTX) and MicroVision (MVIS) suffered steep losses on Tuesday, with each stock falling to fresh 52-week lows as investors reacted to significant setbacks affecting their core business prospects.

The selloff highlighted the risks facing smaller companies operating in biotechnology and emerging technology. 


Heron Therapeutics Inc

Microvision Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.65
Prev Close	$3.67
Open	$3.68
Dividend Yield	0.00%
50-Day Moving Average	$3.78
Beta	1.25
Avg. Volume	1.43M
PE Ratio	-3.01

52-Week High	$15.74
52-Week Low	$2.83
Market Capitalization	$278.48M
EPS (Annual)	-$1.18
Price to Book	0.90
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

FULC Fundamentals